Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Core Insights - Tenaya Therapeutics reported promising data for its gene therapies TN-201 and TN-401, with plans for further data readouts and regulatory alignment in 2026 [1][2] - The company has entered a multi-target research collaboration with Alnylam Pharmaceuticals, which includes an upfront payment and potential milestone payments totaling up to $1.1 billion [11] - Financial results for Q4 and full year 2025 show a net loss reduction, with cash reserves expected to fund operations into the second half of 2027 [8][11] Gene Therapy Programs - TN-201: - Presented promising interim data from the MyPEAK-1 clinical trial for MYBPC3-associated hypertrophic cardiomyopathy (HCM), showing safety and efficacy indicators [3] - All patients improved to New York Heart Association Class I, indicating no limitations in daily living due to symptoms [3] - Enrollment resumed in January 2026 to gather more safety and efficacy data [3][6] - TN-401: - Initial data from the RIDGE-1 clinical trial for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) showed it was well tolerated with no dose-limiting toxicities [4][6] - Clinically meaningful improvements in electrical instability were observed in patients with follow-up beyond six months [6] Small Molecule Development - TN-301: - New preclinical data supports its potential in treating Duchenne muscular dystrophy (DMD) and other cardiac conditions, showing significant functional improvements compared to an approved treatment [5][6] - Plans to advance TN-301 towards clinical trials in 2026 to generate proof-of-activity data [6] Financial Overview - Cash, cash equivalents, and marketable securities increased to $100.5 million as of December 31, 2025, compared to $61.4 million in 2024 [11] - R&D expenses decreased to $14.8 million for Q4 2025 and $68.6 million for the full year, down from $18.7 million and $86.7 million in 2024 [11] - Net loss for Q4 2025 was $20.2 million, or $0.12 per share, a decrease from $23.8 million, or $0.28 per share, in Q4 2024 [11]